Hijacking the human complement inhibitor C4b-binding protein by the sporozoite stage of the


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 22 09 2022
accepted: 02 11 2022
entrez: 8 12 2022
pubmed: 9 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

The complement system is considered the first line of defense against pathogens. Hijacking complement regulators from blood is a common evasion tactic of pathogens to inhibit complement activation on their surfaces. Here, we report hijacking of the complement C4b-binding protein (C4bp), the regulator of the classical and lectin pathways of complement activation, by the sporozoite (SPZ) stage of the

Identifiants

pubmed: 36479121
doi: 10.3389/fimmu.2022.1051161
pmc: PMC9720182
doi:

Substances chimiques

Complement C4b-Binding Protein 0
Complement Inactivating Agents 0
Peptides 0
Vaccines 0
C4BPA protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051161

Informations de copyright

Copyright © 2022 Khattab, Rezola, Barroso, Kyrklund, Pihlajamaa, Freitag, van Gemert, Bousema, Permi, Turunen, Sauerwein, Luty and Meri.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Commun. 2021 Mar 19;12(1):1742
pubmed: 33741975
J Exp Med. 1983 Jun 1;157(6):1947-57
pubmed: 6189951
Vaccine. 2009 Jan 7;27(2):328-35
pubmed: 18984024
Nat Med. 2006 Feb;12(2):220-4
pubmed: 16429144
Exp Parasitol. 1992 Nov;75(3):361-8
pubmed: 1426138
Biopolymers. 2000;55(3):188-206
pubmed: 11074414
Biochemistry. 2006 Apr 11;45(14):4559-68
pubmed: 16584191
PLoS Pathog. 2011 Sep;7(9):e1002197
pubmed: 21909259
Malar J. 2004 Jul 08;3:21
pubmed: 15242514
BMC Med. 2018 Apr 30;16(1):61
pubmed: 29706136
Vaccine. 2008 Dec 30;26 Suppl 8:I49-55
pubmed: 19388165
Parasite Immunol. 1988 Jan;10(1):17-31
pubmed: 3281101
J Immunol. 2016 Feb 1;196(3):1239-48
pubmed: 26700768
Front Microbiol. 2019 Mar 20;10:532
pubmed: 30949145
Front Immunol. 2015 May 26;6:257
pubmed: 26074922
J Biol Chem. 2004 May 21;279(21):21824-32
pubmed: 15007056
Infect Immun. 2018 Jun 21;86(7):
pubmed: 29735521
J Immunol Methods. 2005 Feb;297(1-2):83-95
pubmed: 15777933
J Exp Med. 2005 Jan 3;201(1):27-33
pubmed: 15630135
Nat Med. 2018 May;24(4):401-407
pubmed: 29554084
Cell Host Microbe. 2013 Jan 16;13(1):29-41
pubmed: 23332154
Nat Protoc. 2007;2(7):1705-12
pubmed: 17641635
J Immunol. 2017 Jun 15;198(12):4728-4737
pubmed: 28484054
Cell Rep. 2021 Apr 13;35(2):108996
pubmed: 33852850
FEBS Lett. 2016 Aug;590(15):2418-34
pubmed: 27393384
Cell Host Microbe. 2008 Sep 11;4(3):209-18
pubmed: 18779047
J Infect Dis. 2016 Jan 1;213(1):80-9
pubmed: 26347576
Front Microbiol. 2016 Dec 20;7:2004
pubmed: 28066340
Cell. 1985 Sep;42(2):401-3
pubmed: 2411417
J Mol Biol. 2013 Apr 26;425(8):1302-17
pubmed: 23274142
J Protozool. 1988 Aug;35(3):389-93
pubmed: 3054075
Elife. 2015 Aug 13;4:
pubmed: 26271010
Nat Immunol. 2008 Jul;9(7):725-32
pubmed: 18563083
Nat Med. 2018 May;24(4):408-416
pubmed: 29554083
Exp Parasitol. 1994 May;78(3):294-301
pubmed: 8162961
J Biol Chem. 2005 May 27;280(21):20524-9
pubmed: 15781464
Parasitol Int. 2016 Oct;65(5 Pt B):552-557
pubmed: 26680158

Auteurs

Ayman Khattab (A)

Department of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Department of Nucleic Acid Research, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, New Borg El-Arab, Alexandria, Egypt.

Mikel Rezola (M)

Department of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Marta Barroso (M)

Department of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Mikael Kyrklund (M)

Department of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Department of Bioproducts and Biosystems, Aalto University, Espoo, Finland.

Tero Pihlajamaa (T)

Department of Clinical Chemistry, HUSLAB, Helsinki University Hospital, HUS Diagnostic Center, Helsinki, Finland.

Tobias L Freitag (TL)

Department of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Geert-Jan van Gemert (GJ)

Department of Medical Microbiology, Radboudumc, Nijmegen, Netherlands.

Teun Bousema (T)

Department of Medical Microbiology, Radboudumc, Nijmegen, Netherlands.

Perttu Permi (P)

Department of Chemistry, Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland.

Ossi Turunen (O)

Department of Bioproducts and Biosystems, Aalto University, Espoo, Finland.
School of Forest Sciences, University of Eastern Finland, Joensuu, Finland.

Robert Sauerwein (R)

TropIQ Health Sciences, Nijmegen, Netherlands.

Adrian J F Luty (AJF)

Université de Paris, MERIT, IRD, Paris, France.

Seppo Meri (S)

Department of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
HUSLAB Diagnostic Center, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH